<?xml version="1.0" encoding="UTF-8"?>
<p>Towards the end of 2006, The government of Thailand granted compulsory licenses for two ARV drugs (efavirenz–lopinavir and kaletra) as well as plavix for cardiovascular disease at the end of 2006 and early 2007. In September 2007, the National Drugs Protection Office in Thailand announced its intention to grant compulsory licenses for four cancer drugs: glivec and femara from Novartis, tarceva from Roche, and taxotere from Sanofi–Aventis. In January 2008, the compulsory licenses were granted to femara, tarceva, and taxotere. Glivec was exempt because Novartis had promised to provide glivec free of charge to cancer patients inside the Thai National Health Insurance Program [
 <xref ref-type="bibr" rid="CR14">14</xref>].
</p>
